Abstract
Diabetes is known to cause significant alterations in the retinal vasculature. Indeed, diabetic retinopathy is the leading cause of blindness in those of working age. Considerable evidence is emerging that indicates that retinal neurons are also altered during diabetes. Moreover, many types of neuronal deficits have been observed in animal models and patients prior to the onset of vascular compromise. Such clinical tools as the flash ERG, multifocal ERG, colour vision, contrast sensitivity and short-wavelength automated perimetry, all provide novel means whereby neuronal dysfunction can be detected at early stages of diabetes. The underlying mechanisms that lead to neuronal deficits are likely to be broad. Retinal glial cells play an essential role in maintaining the normal function of the retina. There is accumulating evidence that Muller cells are abnormal during diabetes. They are known to become gliotic, display altered potassium siphoning, glutamate and GABA uptake and are also known to express several modulators of angiogenesis. This review will examine the evidence that neurons and glia are altered during diabetes and the relationship these changes have with vascular compromise.
Keywords: Angiotensin, Muller cell, photoreceptor, pericyte, diabetes
Current Pharmaceutical Design
Title: Neuronal and Glial Cell Abnormality as Predictors of Progression of Diabetic Retinopathy
Volume: 13 Issue: 26
Author(s): Erica L. Fletcher, Joanna A. Phipps, Michelle M. Ward, Theresa Puthussery and Jennifer L. Wilkinson-Berka
Affiliation:
Keywords: Angiotensin, Muller cell, photoreceptor, pericyte, diabetes
Abstract: Diabetes is known to cause significant alterations in the retinal vasculature. Indeed, diabetic retinopathy is the leading cause of blindness in those of working age. Considerable evidence is emerging that indicates that retinal neurons are also altered during diabetes. Moreover, many types of neuronal deficits have been observed in animal models and patients prior to the onset of vascular compromise. Such clinical tools as the flash ERG, multifocal ERG, colour vision, contrast sensitivity and short-wavelength automated perimetry, all provide novel means whereby neuronal dysfunction can be detected at early stages of diabetes. The underlying mechanisms that lead to neuronal deficits are likely to be broad. Retinal glial cells play an essential role in maintaining the normal function of the retina. There is accumulating evidence that Muller cells are abnormal during diabetes. They are known to become gliotic, display altered potassium siphoning, glutamate and GABA uptake and are also known to express several modulators of angiogenesis. This review will examine the evidence that neurons and glia are altered during diabetes and the relationship these changes have with vascular compromise.
Export Options
About this article
Cite this article as:
Fletcher L. Erica, Phipps A. Joanna, Ward M. Michelle, Puthussery Theresa and Wilkinson-Berka L. Jennifer, Neuronal and Glial Cell Abnormality as Predictors of Progression of Diabetic Retinopathy, Current Pharmaceutical Design 2007; 13 (26) . https://dx.doi.org/10.2174/138161207781662920
DOI https://dx.doi.org/10.2174/138161207781662920 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases
Current Vascular Pharmacology Subthreshold Laser Therapy for Diabetic Macular Edema: Metabolic and Safety Issues
Current Medicinal Chemistry Neuroprotective Strategies in Glaucoma
Current Pharmaceutical Design Lipid Nanocarriers (LNC) and their Applications in Ocular Drug Delivery
Current Medicinal Chemistry Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Diabetes Exacerbates Nanoparticles Induced Brain Pathology
CNS & Neurological Disorders - Drug Targets Targeting Plasminogen Activator Inhibitor-1: Role in Cell Signaling and the Biology of Domain-Specific Knock-in Mice
Current Drug Targets Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry Angiogenesis as Risk Factor for Plaque Vulnerability
Current Pharmaceutical Design Stable Angina Pectoris: Current Medical Treatment
Current Pharmaceutical Design Anti-VEGF Therapy for Retinal Vein Occlusions
Current Drug Targets Update on Pharmacologic Retinal Vascular Toxicity
Current Pharmaceutical Design Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Recent Advances in Hematopoietic Stem Cell-Mediated Regeneration
Recent Patents on Regenerative Medicine Plasticity and Maintenance of Hematopoietic Stem Cells During Development
Recent Patents on Biotechnology Purinergic Signalling and Endothelium
Current Vascular Pharmacology Recent Development in Applications of Important Biopolymer Chitosan in Biomedicine, Pharmaceuticals and Personal Care Products
Current Tissue Engineering (Discontinued) Controversies in NSAIDs Use in Cataract Surgery
Current Pharmaceutical Design Anti-Vegf Therapy for Ocular Diseases: Present and Future
Current Drug Targets Endothelin-1 Signaling in Vascular Physiology and Pathophysiology
Current Vascular Pharmacology